| ［1］ |
Menter A, Strober BE, Kaplan DH, et al. Joint AAD⁃NPF guidelines of care for the management and treatment of psoriasis with biologics［J］. J Am Acad Dermatol, 2019,80（4）:1029⁃1072. doi: 10.1016/j.jaad.2018.11.057.
|
| ［2］ |
中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2018简版）［J］. 中华皮肤科杂志, 2019,52（4）:223⁃230. doi: 10.3760/cma.j.issn.0412⁃4030.2019.04.001.
|
| ［3］ |
Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian guidelines for the management of plaque psoriasis 2009［J］. J Cutan Med Surg, 2016,20（5）:375⁃431. doi: 10.1177/1203475416655705.
|
| ［4］ |
Poelman SM, Keeling CP, Metelitsa AI. Practical guidelines for managing patients with psoriasis on biologics: an update［J］. J Cutan Med Surg, 2019,23（1_suppl）:3S⁃12S. doi: 10.1177/1203 475418811347.
|
| ［5］ |
Fujita H, Terui T, Hayama K, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP［J］. J Dermatol, 2018,45（11）:1235⁃1270. doi: 10.1111/1346⁃8138.14523.
|
| ［6］ |
Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double⁃blind, placebo⁃controlled multicenter trial［J］. Chin Med J （Engl）, 2012,125（11）:1845⁃1851. doi: 10.3760/ cma.j.issn.0366⁃6999.2012.11.001.
|
| ［7］ |
Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque⁃type psoriasis: a randomized, double⁃blind, placebo⁃controlled trial［J］. J Am Acad Dermatol, 2004,51（4）:534⁃542. doi: 10.1016/j.jaad.2004.02.021.
|
| ［8］ |
Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate⁃to⁃severe psoriasis: a phase III, multicentre, double⁃blind trial［J］. Lancet, 2005,366（9494）:1367⁃1374. doi: 10.1016/S0140⁃6736（05）67566⁃6.
|
| ［9］ |
Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double⁃blind, phase 3 trial［J］. Lancet, 2017,390（10089）:40⁃49. doi: 10.1016/S0140⁃6736（17）31189⁃3.
|
| ［10］ |
Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate⁃to⁃severe plaque psoriasis: results from a phase 3, randomized, placebo⁃controlled, double⁃blind study［J］. J Eur Acad Dermatol Venereol, 2017,31（1）:89⁃95. doi: 10.1111/jdv.13746.
|
| ［11］ |
Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial［J］. J Am Acad Dermatol, 2008,58（1）:106⁃115. doi: 10. 1016/j.jaad.2007.09.010.
|
| ［12］ |
Gordon K, Papp K, Poulin Y, et al. Long⁃term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open⁃label extension study for patients from REVEAL［J］. J Am Acad Dermatol, 2012,66（2）:241⁃251. doi: 10.1016/j.jaad.2010.12.005.
|
| ［13］ |
Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long⁃term treatment of psoriatic arthritis: 2⁃year data from the adalimumab effectiveness in psoriatic arthritis trial （ADEPT）［J］. Ann Rheum Dis, 2009,68（5）:702⁃709. doi: 10.1136/ard.2008.092767.
|
| ［14］ |
Kimball AB, Gordon KB, Fakharzadeh S, et al. Long⁃term efficacy of ustekinumab in patients with moderate⁃to⁃severe psoriasis: results from the PHOENIX 1 trial through up to 3 years［J］. Br J Dermatol, 2012,166（4）:861⁃872. doi: 10.1111/j.1365⁃2133.2012.10901.x.
|
| ［15］ |
Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque⁃type psoriasis: results from a phase 3 clinical trial （LOTUS）［J］. J Drugs Dermatol, 2013,12（2）:166⁃174.
|
| ［16］ |
Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin⁃12/23 monoclonal antibody, in patients with psoriasis: 76⁃week results from a randomised, double⁃blind, placebo⁃controlled trial （PHOENIX 1）［J］. Lancet, 2008,371（9625）:1665⁃1674. doi: 10.1016/S0140⁃6736（08）60725⁃4.
|
| ［17］ |
Kimball AB, Papp KA, Wasfi Y, et al. Long⁃term efficacy of ustekinumab in patients with moderate⁃to⁃severe psoriasis treated for up to 5 years in the PHOENIX 1 study［J］. J Eur Acad Dermatol Venereol, 2013,27（12）:1535⁃1545. doi: 10.1111/ jdv.12046.
|
| ［18］ |
Landells I, Marano C, Hsu MC, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate⁃to⁃severe plaque psoriasis: results of the randomized phase 3 CADMUS study［J］. J Am Acad Dermatol, 2015,73（4）:594⁃603. doi: 10.1016/j.jaad. 2015.07.002.
|
| ［19］ |
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial［J］. J Am Acad Dermatol, 2015,73（3）:400⁃409. doi: 10.1016/j.jaad. 2015.05.013.
|
| ［20］ |
Ohtsuki M, Terui T, Ozawa A, et al. Japanese guidance for use of biologics for psoriasis （the 2013 version）［J］. J Dermatol, 2013,40（9）:683⁃695. doi: 10.1111/1346⁃8138.12239.
|
| ［21］ |
Smith CH, Jabbar⁃Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017［J］. Br J Dermatol, 2017,177（3）:628⁃636. doi: 10.1111/bjd.15665.
|
| ［22］ |
González⁃Álvaro I, Martínez⁃Fernández C, Dorantes⁃Calderón B, et al. Spanish rheumatology society and hospital pharmacy society consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis［J］. Rheumatology （Oxford）, 2015,54（7）:1200⁃1209. doi: 10.1093/rheumatology/keu461.
|
| ［23］ |
Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate⁃to⁃severe psoriasis in adults［J］. J Eur Acad Dermatol Venereol, 2019,33（3）:464⁃483. doi: 10.1111/jdv.15340.
|
| ［24］ |
Nast A, Amelunxen L, Augustin M, et al. S3 Guideline for the treatment of psoriasis vulgaris, update ⁃ short version part 1 ⁃ systemic treatment［J］. J Dtsch Dermatol Ges, 2018,16（5）:645⁃669. doi: 10.1111/ddg.13516.
|
| ［25］ |
Armstrong AW, Bagel J, Van Voorhees AS, et al. Combining biologic therapies with other systemic treatments in psoriasis: evidence⁃based, best⁃practice recommendations from the Medical Board of the National Psoriasis Foundation［J］. JAMA Dermatol, 2015,151（4）:432⁃438. doi: 10.1001/jamadermatol. 2014.3456.
|
| ［26］ |
Owczarczyk⁃Saczonek A, Owczarek W, Osmola⁃Mańkowska A, et al. Secondary failure of TNF⁃α inhibitors in clinical practice［J］. Dermatol Ther, 2019,32（1）:e12760. doi: 10.1111/dth.12760.
|
| ［27］ |
Boehncke WH, Brembilla NC. Immunogenicity of biologic therapies: causes and consequences［J］. Expert Rev Clin Immunol, 2018,14（6）:513⁃523. doi: 10.1080/1744666X.2018.1468753.
|
| ［28］ |
Amin M, No DJ, Egeberg A, et al. Choosing first⁃line biologic treatment for moderate⁃to⁃severe psoriasis: what does the evidence say?［J］. Am J Clin Dermatol, 2018,19（1）:1⁃13. doi: 10.1007/s40257⁃017⁃0328⁃3.
|
| ［29］ |
Bronckers IM, Paller AS, van Geel MJ, et al. Psoriasis in children and adolescents: diagnosis, management and comorbidities［J］. Paediatr Drugs, 2015,17（5）:373⁃384. doi: 10.1007/s40272⁃015⁃0137⁃1.
|
| ［30］ |
Gatti J, Lindstrom JA, Beitz J. Reconsideration of 2008 decision: food and drug administration approval of etanercept for systemic treatment of moderate to severe pediatric psoriasis［J］. Pediatr Dermatol, 2018,35（5）:688⁃689. doi: 10.1111/pde.13557.
|
| ［31］ |
de Jager ME, de Jong EM, van de Kerkhof PC, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review［J］. J Am Acad Dermatol, 2010,62（6）:1013⁃1030. doi: 10.1016/j.jaad.2009.06.048.
|
| ［32］ |
Motaparthi K, Stanisic V, Van Voorhees AS, et al. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti⁃tumor necrosis factor⁃alfa inhibitors or other immunosuppressive agents in patients with psoriasis［J］. J Am Acad Dermatol, 2014,70（1）:178⁃186. doi: 10.1016/j.jaad.2013. 08.049.
|
| ［33］ |
Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF⁃α antagonists: a systematic review and meta⁃analysis of randomised controlled trials［J］. BMJ Open, 2017,7（3）:e012567. doi: 10.1136/bmjopen⁃2016⁃012567.
|
| ［34］ |
肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识［J］. 中华风湿病学杂志, 2013,17（8）:508⁃512. doi: 10.3760/cma.j.issn.1007⁃7480.2013.08.002.
|
| ［35］ |
王刚. 皮肤科生物制剂的不良反应及对策［J］. 中华皮肤科杂志, 2019,52（2）:77⁃80. doi: 10.3760/cma.j.issn.0412⁃4030.2019. 02.001.
|
| ［36］ |
Dressler C, Rosumeck S, Werner RN, et al. Methods report: European S3⁃Guideline on the systemic treatment of psoriasis vulgaris ⁃ update apremilast and secukinumab ⁃ EDF in cooperation with EADV and IPC［J］. J Eur Acad Dermatol Venereol, 2017,31（12）:1964⁃1977. doi: 10.1111/jdv.14470.
|
| ［37］ |
Nast A, Spuls PI, van der Kraaij G, et al. European S3⁃Guideline on the systemic treatment of psoriasis vulgaris ⁃ update apremilast and secukinumab ⁃ EDF in cooperation with EADV and IPC［J］. J Eur Acad Dermatol Venereol, 2017,31（12）:1951⁃1963. doi: 10.1111/jdv.14454.
|
| ［38］ |
Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti⁃tumor necrosis factor agents in pregnant patients with inflammatory bowel disease［J］. Clin Gastroenterol Hepatol, 2013,11（3）:286⁃292, e24. doi: 10.1016/j.cgh.2012.11.011.
|
